Shares of Haemonetics Corporation (NYSE: HAE) skyrocketed 33.75% in intraday trading on Thursday, following the release of its second quarter fiscal 2026 financial results that significantly surpassed analyst expectations. The medical technology company, specializing in blood and plasma supplies and services, reported strong earnings and raised its full-year guidance, sparking intense investor enthusiasm.

Haemonetics posted quarterly revenue of $327.3 million, beating the FactSet consensus estimate of $311.5 million. While this represents a 5% decrease compared to the same period last year, primarily due to the impact of its CSL Plasma business, the company's organic revenue excluding CSL increased by an impressive 9.4% for the quarter. The adjusted earnings per share (EPS) came in at $1.27, substantially higher than the FactSet estimate of $0.99 and marking a 13.39% increase from the $1.12 per share reported in the same quarter last year.

In response to the strong performance, Haemonetics raised the lower end of its fiscal 2026 adjusted EPS guidance to $4.80 to $5.00, up from the previous range of $4.70 to $5.00. This upward revision in guidance signals management's confidence in the company's future performance. Chris Simon, Haemonetics' Chief Executive, stated, "With the majority of our businesses outperforming and targeted actions underway to strengthen commercial execution in Interventional Technologies, we are firmly on track to deliver our updated fiscal year 2026 guidance and long-range plan objectives." The company also narrowed its total revenue guidance, now expecting a decline of 1% to 4% for the fiscal year, compared to the previous outlook of a 3% to 6% decrease.